natgillin/translations-raw huggingface dataset:
Sevohale 100% v/v væske til inhalationsdamp til hunde sevofluran.
Sevohale 100% v/v Inhalation vapour, liquid for dogs. sevoflurane
Sevohale bør indgives via en fordamper, der er kalibreret specifikt til anvendelse med sevofluran, således at den givne koncentration kan kontrolleres nøjagtigt.
Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled.
Sevohale er et "generisk lægemiddel".
Sevohale is a ‘generic medicine’.
Sevohale er et generisk anæstetisk lægemiddel, der anvendes til at producere og opretholde generel anæstesi (bevidstløshed) hos hunde.
Sevohale is a general anaesthetic medicine that is used to produce and maintain general anaesthesia (loss of consciousness) in dogs.
Sevohale er tilgængelig som en væske, der omdannes til damp ved opvarmning, og udleveres kun efter recept.
Sevohale is available as a liquid that becomes a vapour when it is heated and can only be obtained with a prescription.
Sevohale indeholder ingen stabilisator o påvirker ikke på nogen måde kalibreringen eller funktionen af disse fordampere.
Sevohale contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way.
Sevohale skal tilføres via en fordamper, der er kalibreret specifikt til anvendelse med sevofluran, således at den givne koncentration kan kontrolleres nøjagtigt.
Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled.
Sevohale1 sevofluran
Sevohale1 sevoflurane
SF-36 (gennemsnitlig ændring i de score for mentale og fysiske komponenter) var signifikant højere i den subkutane tocilizumab arm (6,5 og 5,3) sammenlignet med placebo (3,8 og 2,9).
SF-36 (mean change in mental and physical component scores) was significantly greater with tocilizumab subcutaneous group (6.5 and 5.3) versus placebo (3.8 and 2.9).
SF-36 PHS MCID
n=197 0.9
SGLT2 absorberer glukose tilbage fra urinen til blodbanen, når blodet filtreres i nyrerne.
SGLT2 absorbs glucose from the urine into the bloodstream as the blood is filtered in the kidneys.
SGLT2 er et protein, der transporterer glukose fra urinen tilbage til blodbanen, når blodet filtreres i nyrerne.
SGLT2 is a protein that absorbs glucose back from the urine into the bloodstream as the blood is filtered in the kidneys.
SGLT2 er et protein, der transporterer glukose tilbage fra urinen til blodbanen, når blodet filtreres i nyrerne.
SGLT2 is a protein that absorbs glucose from the urine into the bloodstream as the blood is filtered in the kidneys.
Sham-injektion (n=238)
Sham (n=238)
sham-kontrolleret arm krydset over til ranibizumab
sham-controlled arm crossed-over to ranibizumab
Sham/Lucentis 0,5 mg (n=132)
0.5 mg (n=132)
Shamir & SAT2 Saudi Arabia
O1 BFS, Asia1 Shamir and SAT2 Saudi Arabia
Shannon Industrial Estate Shannon, Co.
Shannon Industrial Estate Shannon, Co. Clare
Shannon Industrial Estate,
Shannon, Industrial Estate,
Shellac Povidon
Printing ink
Shellac Povidon
Propylene glycol Shellac Povidone
Shellac Povidon
Shellac Povidone
Shellac Propylenglycol Indigotin I (E132).
Propylene glycol Indigo carmine (E 132)
Shellac-glasur (bleget, afvokset) 45 % Jernoxid, sort (E172)
Shellac (bleached, de-waxed) glaze 45% Iron oxide black (E172)
Shellacglasering (20 % esterificeret) Propylenglycol
Shellac glaze (20% esterified) Propylene glycol
Shering-Plough Labo NV Industriepark 30 – Zone A B-2220 Heist-op-den-Berg Belgien
Shering-Plough Labo NV Industriepark 30 – Zone A B-2220 Heist-op-den-Berg Belgium
Shingles Prevention Study (SPS) hos forsøgspersoner på 60 år og derover
Shingles Prevention Study (SPS) in Subjects 60 years of age and older:
Shionogi Limited 33 Kingsway London WC2B 6UF Storbritannien
Shionogi Limited 33 Kingsway London WC2B 6UF United Kingdom
Shire Human Genetic Therapies AB, Vasagatan 7
Shire Human Genetic Therapies AB Vasagatan 7
Shire leverer en årlig opdatering af alle offentliggjorte data vedrørende anagrelids virkning og sikkerhed hos ET-patienter som en del af den årlige revurdering.
Shire will provide an annual update of all published data concerning the efficacy and safety of anagrelide in ET patients as part of the Annual Reassessment.
Shock
hock,
Shock
hock;
Shock (herunder kardiogent shock)
Shock (including cardiogenic shock)
Shock, herunder kardiogent shock.
Shock (including cardiogenic shock).
shock, infarkt, hæmatom, lymfocele, angiopati, arteriel fibrose
shock, infarction, haematoma, lymphocele, angiopathy, arterial fibrosis
shock;
hock;
Shotton Lane, Cramlington Northumberland NE23 3 JU Storbritannien
United Kingdom United Kingdom
Shotton Lane, Cramlington Northumberland NE23 3JU Storbritannien
Shotton Lane, Cramlington Northumberland NE23 3JU United Kingdom
Shunttrombose Trombocytose
Shunt thrombosis Thrombocytosis
Shunttrombose*
Shunt thrombosis
Si coincide la presentación de un IPS con la actualización del PGR, ambos documentos se pueden presentar conjuntamente.
If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
Si el aclaramiento de creatinina es ≤ 60 ml/min, la dosis inicial de Siklos debe reducirse en un 50 %.
In patients with a creatinine clearance ≤ 60 ml/min the initial Siklos dose should be decreased by 50%.
Si el paciente no puede tragar los comprimidos, podrán disolverse inmediatamente antes de su uso en una pequeña cantidad de agua utilizando una cucharilla.
For patients who are not able to swallow the tablets, these can be disintegrated immediately before use in a small quantity of water in a teaspoon.
Si experimenta (o ha experimentado) alguno de estos trastornos, dígaselo a su médico.
If you experience (or have experienced) any of the above, please tell your doctor.
Si experimenta cualquiera de los siguientes trastornos, avise inmediatamente a su médico:
Tell your doctor immediately if you experience any of the following:
Si experimenta efecto adverso, consulte a su médico o farmacéutico o enfermera, incluso si se trata de efectos adversos que no aparecen en este prospecto.
If you get any side effects, talk to your doctor or, pharmacist or nurse.
Si experimenta efectos adversos, consulte a su médico, o farmacéutico o enfermero, incluso si se trata de efectos adversos que no aparecen en este prospecto.
If you get any side effects, talk to your doctor, or pharmacist or nurse.
Si interrumpe el tratamiento con Siklos
If you stop taking Siklos
Si las cifras de los hemogramas se encuentran dentro de los límites de toxicidad, se suspenderá temporalmente la administración de Siklos hasta que dichas cifras vuelvan a la normalidad.
If blood counts are within the toxic range Siklos should be temporarily discontinued until blood counts recover.
Si no hay respuesta (reaparición de las crisis o mantenimiento de la frecuencia de éstas) se puede aumentar la dosis en incrementos de 2,5 a 5 mg/kg de peso corporal/día utilizando la concentración más apropiada.
In case of non-response (re-occurrence of crises or no decrease in crisis rate) the daily dose may be increased by steps of 2.5 to 5 mg/kg b.w./day using the most appropriate strength.
Si no puede tragar los comprimidos, puede disolverlos en agua inmediatamente antes de su uso:
If you cannot swallow the tablets, you can disintegrate them in water immediately before use:
Si observa alguna de las siguientes reacciones adversas a Siklos, informe a su médico cuanto antes:
Tell your doctor as soon as possible if you notice any of the following side effects of Siklos:
Si olvidó tomar Siklos
If you forget to take Siklos
Si para lograr la dosis necesaria tiene que partir el comprimido en dos o cuatro partes, debe hacerlo lejos de donde haya alimentos.
In case the prescribed dose requires breaking the tablet in halves or quarters, this should be done out of the reach of food.
Si se aumenta la dosis de forma gradual, estos efectos pueden ser menos intensos (ver sección 4.2).
Gradual dose titration may help to diminish these effects (see section 4.2).
Si se observa una depresión acusada de la función de la médula ósea, se suspenderá el tratamiento con Siklos.
Treatment with Siklos should be discontinued if bone marrow function is markedly depressed.
Si se rompe un comprimido, toda persona que no esté tomando Siklos (en especial las mujeres embarazadas) debe evitar entrar en contacto con los fragmentos.
Any person, in particular pregnant women, who are not taking Siklos should avoid direct contact with the parts when breaking a tablet.
Si tiene alguna duda, consulte a su médico, o farmacéutico o enfermero.
If you have any further questions, ask your doctor, or pharmacist or nurse.
Si tiene alguna pregunta, por favor consulte a su médico o farmacéutico o enfermera.
If you have any question please ask your doctor or pharmacist or nurse.
Si tiene cualquier otra duda sobre el uso de este producto, pregunte a su médico o farmacéutico.
If you have any further question on the use of this medicine, ask your doctor or pharmacist.
Si toma más Siklos del que debiera
If you take more Siklos than you should
Si toma más Siklos del que debiera o si lo toma un niño, póngase inmediatamente en contacto con su médico o con el hospital más cercano, porque puede necesitar tratamiento médico urgente.
If you take more Siklos than you should or if a child has taken any, contact your doctor or the nearest hospital immediately as you may need urgent medical treatment.
Si un paciente sigue sin responder a pesar de recibir la dosis máxima de hidroxicarbamida (35 mg/kg p.c./día) durante tres a seis meses, se considerará la posibilidad de suspender definitivamente la administración de Siklos.
In the event a patient does still not respond when treated with the maximum dose of hydroxycarbamide (35 mg/kg b.w./day) over three to six months, permanent discontinuation of Siklos should be considered.
Si una dosis produce toxicidad hematológica, no debe probarse más de dos veces.
A dose producing haematological toxicity should not be tried more than two times.
SI- enheder = mol /l
SI unit = mol/l)
SI-1.000 Ljubljana Tel: +386 1 401 18 30
SI-1000 Ljubljana Tel: +386 1 401 18 30
SI-1236 Trzin
PharmaSwiss d.o.o.
SIA AstraZeneca Latvija
SIA AstraZeneca Latvija Tel: +371 67377100
SIA Merck Sharp & Dohme Latvija Tel: + 371 67364224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com.
SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
SIA “Merck Sharp & Dohme Latvija” Tel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com.
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com.
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com.
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija, Tlf: +371 67364 224
SIA Merck Sharp & Dohme Latvija, Tel: +371 67364 224
SIA Merck Sharp & Dohme LatvijaTel: +371 67364 224 msd_lv@merck.com
SIA Merck Sharp & Dohme Latvija Tel: +371 67364 224 msd_lv@merck.com
Sialanar 320 mikrogram/ml, oral opløsning
Sialanar 320 micrograms /ml oral solution
Sialanar 320 mikrogram/ml, oral opløsning
Sialanar 320 micrograms/ml oral solution
Sialanar forventes ikke at give abstinenser, når behandlingen stoppes.
Withdrawal effects are not expected when stopping Sialanar.
Sialanar indgives gennem munden.
Sialanar should be taken by mouth.
Sialanar må ikke anvendes hos en pige/en ung kvinde, hvis hun er (eller kan være) gravid eller ammer (se ovenstående punkt "Giv ikke Sialanar til barnet/den unge, hvis han/hun:" under punkt 2).
Sialanar must not be given if the patient is pregnant (or could be pregnant), or is breast-feeding (see section 2 ‘Do not give’).
Sicor Biotech filiāle Latvijā
Sicor Biotech filiāle Latvijā Tel: +371 67 323 666
Sid eller lig ned i en afslappet, behagelig stilling.
Sit or lie in a relaxed, comfortable position.
sidde stille koncentrere sig.
it still concentrate.
Side 1 (forside) Side 2
Page 1 (front) Page 2
Side 10 Side 11
Page 10 Page 11
Side 12 Side 13
Page 12 Page 13
Side 14 Side 15
Page 14 Page 15
Side 16 Side 17
Page 16 Page 17
Side 18 Side 19
Page 18 Page 19
Side 2
Page 1/1
Side 2 Side 3
Page 2 Page 3
Side 2/2
EMA/55700/2016 Page 2/2
Side 20 Side 21
Page 20 Page 21
Side 22 Side 23
Page 22 Page 23
Side 24 Side 25
Page 24 Page 25
Side 26 Side 27
Page 26 Page 27
Side 28 Side 29
Page 28 Page 29
Side 3 (indvendig venstre side) Side 4 (indvendig midterside)
Page 3 (inside left) Page 4 (inside centre)
Side 3/3
Page 2/2
Side 30 Side 31
Page 30 Page 31
Side 32 Side 33
Page 32 Page 33
Side 34 Side 35
Page 34 Page 35
Side 36 Side 37
Page 36 Page 37
Side 38 Side 39
Page 38 Page 39
Side 4 Side 5
Page 4 Page 5
Side 5 (indvendig højre side) Side 6 (bagside)
Page 5 (inside right) Page 6 (back)
Side 6 Side 7
Page 6 Page 7
Side 8 Side 9
Page 8 Page 9
Side med etiketter og selvklæbende etiketter med stregkode
Page of barcode labels and sticker
SIDE MED SELVKLAEBENDE ETIKETTER
PAGE OF LABELS AND STICKERS
Side med selvklæbende etiketter
Data sheet for patient documentation Bar code labels and sticker
Side med selvklæbende etiketter
Data sheet for patient documentation Page of labels and sticker
Sideløbende aktiv og passiv immunisering (vaccination i nødstilfælde)
Concurrent active and passive immunisation (emergency vaccination)
Sideløbende med Kuvan-behandlingen er det nødvendigt med tæt kontrol af fenylalanin- og det samlede proteinindtag via kosten for at sikre tilstrækkelig kontrol af fenylalaninniveauet i blodet og ernæringsbalancen.
Active management of dietary phenylalanine and overall protein intake while taking Kuvan is required to ensure adequate control of blood phenylalanine levels and nutritional balance.
Siden 2007 er resistens forbundet med H275Y- mutation i sæsonbestemte H1N1-stammer blevet udbredt.
Since 2007 resistance associated H275Y mutation in seasonal H1N1 strains has become widespread.
Siden man imidlertid ikke i øjeblikket har kendskab til nogen DPD-inducere, kan interaktionen mellem en DPD-inducer og Teysuno ikke evalueres.
However, since no DPD inducers are currently known, the interaction between a DPD inducer and Teysuno can not be evaluated.
Sideroblastisk anæmi; leukopeni
sideroblastic anaemia, leukopenia
Sidst i denne indlægsseddel er der detaljerede instruktioner i, hvordan læger og sundhedspersonale skal klargøre Lartruvo til infusion (se 'Instruktioner i håndtering').
Detailed instructions for your doctor or your nurse on how to prepare Lartruvo infusion are included at the end of this package leaflet (see ‘Handling instructions’).
Sidste dag i perioden på 7 dage ved stuetemperatur: / /
End of 7 days period at room temperature: / /
Sidste rapport i 2023
Final report by 2023
Sidstnævnte indeholdt 360 ELISA-enheder formalininaktiveret hapatitis A-virus og 10 mikrogram rekombinant hepatitis B- overfladeantigen.
The latter contained 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface antigen.
Sidstnævnte synes at være relateret til thalidomid og forekom ved eksponering, der var over 2,4 gange større end human eksponering.
The latter appears to be related to thalidomide and occurred at exposures greater than 2.4 fold the human exposure.
Siemensstrasse 107 A-1210 Wien Østrig
Intervet GesmbH Siemensstrasse 107 A-1210 Wien Austria
Siempre que se manipule Siklos, lávese las manos antes y después de tocar los comprimidos.
Anyone handling Siklos should wash their hands before and after contact with the tablets.
Siena Italien
Siena Italy
Siena, Italien
Siena, Italy
Sifrol 0,088 mg er hvide, runde, flade tabletter og er uden delekærv.
SIFROL 0.088 mg tablets are white, of round shape, flat, and without scoring.
SIFROL 0,088 mg tabletter pramipexol
SIFROL 0.088 mg tablets Pramipexole
Sifrol 0,088 mg tabletter Sifrol 0,18 mg tabletter Sifrol 0,35 mg tabletter Sifrol 0,7 mg tabletter Sifrol 1,1 mg tabletter
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets SIFROL 1.1 mg tablets
Sifrol 0,088 mg tabletter Sifrol 0,18 mg tabletter Sifrol 0,35 mg tabletter Sifrol 0,7 mg tabletter Sifrol 1,1 mg tabletter pramipexol
SIFROL 0.088 mg tablets SIFROL 0.18 mg tablets SIFROL 0.35 mg tablets SIFROL 0.7 mg tablets SIFROL 1.1 mg tablets Pramipexole
Sifrol 0,18 mg og Sifrol 0,35 mg er hvide, ovale og flade tabletter.
SIFROL 0.18 mg tablets and SIFROL 0.35 mg tablets are white, of oval shape, and flat.
SIFROL 0,18 mg tabletter pramipexol
SIFROL 0.18 mg tablets Pramipexole
Sifrol 0,26 mg depottabletter EU/1/97/050/013-015
SIFROL 0.26 mg prolonged-release tablets EU/1/97/050/013-015
SIFROL 0,26 mg depottabletter pramipexol
SIFROL 0.26 mg prolonged-release tablets Pramipexole
Sifrol 0,26 mg depottabletter Sifrol 0,52 mg depottabletter Sifrol 1,05 mg depottabletter Sifrol 1,57 mg depottabletter Sifrol 2,1 mg depottabletter Sifrol 2,62 mg depottabletter Sifrol 3,15 mg depottabletter
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets
Sifrol 0,26 mg depottabletter Sifrol 0,52 mg depottabletter Sifrol 1,05 mg depottabletter Sifrol 1,57 mg depottabletter Sifrol 2,1 mg depottabletter Sifrol 2,62 mg depottabletter Sifrol 3,15 mg depottabletter pramipexol
SIFROL 0.26 mg prolonged-release tablets SIFROL 0.52 mg prolonged-release tablets SIFROL 1.05 mg prolonged-release tablets SIFROL 1.57 mg prolonged-release tablets SIFROL 2.1 mg prolonged-release tablets SIFROL 2.62 mg prolonged-release tablets SIFROL 3.15 mg prolonged-release tablets Pramipexole
Sifrol 0,26 mg depottabletter.
two SIFROL 0.26 mg prolonged-release tablets.
Sifrol 0,26 mg og 0,52 mg depottabletter er hvide til råhvide, runde og har facetslebne kanter.
SIFROL 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges.
SIFROL 0,35 mg tabletter pramipexol
SIFROL 0.35 mg tablets Pramipexole
Sifrol 0,52 mg depottablet, ELLER
One SIFROL 0.52 mg prolonged-release tablet, OR
Sifrol 0,52 mg depottabletter EU/1/97/050/016-018
SIFROL 0.52 mg prolonged-release tablets EU/1/97/050/016-018
SIFROL 0,52 mg depottabletter pramipexol
SIFROL 0.52 mg prolonged-release tablets Pramipexole
Sifrol 0,52 mg depottabletter, ELLER
two SIFROL 0.52 mg prolonged-release tablets, OR
Sifrol 0,7 mg og Sifrol 1,1 mg er hvide, runde og flade tabletter.
SIFROL 0.7 mg tablets and SIFROL 1.1 mg tablets are white, of round shape, and flat.
SIFROL 0,7 mg tabletter pramipexol
SIFROL 0.7 mg tablets Pramipexole
Sifrol 1,05 mg depottabletter EU/1/97/050/019-021
SIFROL 1.05 mg prolonged-release tablets EU/1/97/050/019-021
SIFROL 1,05 mg depottabletter pramipexol
SIFROL 1.05 mg prolonged-release tablets Pramipexole
Sifrol 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg og 3,15 mg depottabletter er hvide til råhvide og ovale.
SIFROL 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg prolonged-release tablets are white to off- white and of oval shape.
Sifrol 1,1 mg tabletter
SIFROL 1.1 mg tablets
Sifrol 1,1 mg tabletter EU/1/97/050/009-010
SIFROL 1.1 mg tablets EU/1/97/050/009-010
SIFROL 1,1 mg tabletter pramipexol
SIFROL 1.1 mg tablets Pramipexole
SIFROL 1,57 mg depottabletter
SIFROL 1.57 mg prolonged-release tablets
Sifrol 1,57 mg depottabletter EU/1/97/050/028-030
SIFROL 1.57 mg prolonged-release tablets EU/1/97/050/028-030
SIFROL 1,57 mg depottabletter pramipexol
SIFROL 1.57 mg prolonged-release tablets Pramipexole
Sifrol 2,1 mg depottabletter EU/1/97/050/022-024
SIFROL 2.1 mg prolonged-release tablets EU/1/97/050/022-024
SIFROL 2,1 mg depottabletter pramipexol
SIFROL 2.1 mg prolonged-release tablets Pramipexole
SIFROL 2,62 mg depottabletter
SIFROL 2.62 mg prolonged-release tablets
Sifrol 2,62 mg depottabletter EU/1/97/050/031-033
SIFROL 2.62 mg prolonged-release tablets EU/1/97/050/031-033
SIFROL 2,62 mg depottabletter pramipexol
SIFROL 2.62 mg prolonged-release tablets Pramipexole
Sifrol 3,15 mg depottabletter EU/1/97/050/025-027
SIFROL 3.15 mg prolonged-release tablets EU/1/97/050/025-027
SIFROL 3,15 mg depottabletter pramipexol
SIFROL 3.15 mg prolonged-release tablets Pramipexole
Sifrol bruges til behandling af voksne patienter med symptomer på Parkinsons sygdom.
SIFROL is used to: treat the symptoms of primary Parkinson’s disease in adults.
Sifrol bruges til: behandling af voksne patienter med symptomer på Parkinsons sygdom.
SIFROL is used to treat the symptoms of primary Parkinson’s disease in adults.
Sifrol depottabletter er specialfremstillede tabletter, hvor det aktive stof langsomt frigives efter indtagelse af tabletten.
SIFROL prolonged-release tablets is a specially designed tablet from which the active ingredient is gradually released, once the tablet has been ingested.
Sifrol indeholder det aktive stof pramipexol, der er en såkaldt dopaminagonist, som stimulerer specielle receptorer i hjernen (dopaminreceptorerne).
SIFROL contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Sifrol indeholdet det aktive stof pramipexol, der er en såkaldt dopaminagonist, som stimulerer specielle receptorer i hjernen (dopaminreceptorerne).
SIFROL contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Sifrol kan enten tages sammen med mad eller alene.
SIFROL can be taken with or without food.
Sifrol kan nedsætte mælkeproduktionen og kan også overføres til din baby via brystmælk.
Also, it can pass into the breast milk and can reach your baby.
Sifrol kan tages alene eller i kombination med levodopa (medicin til behandling af Parkinsons sygdom)
It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease).
Sifrol kan tages alene eller i kombination med levodopa (medicin til behandling af Parkinsons sygdom) behandling af voksne patienter med symptomer på moderat til svær restless legs syndrom (RLS), en sygdom, der giver uro i benene.
It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease). treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.
Sifrol må ikke anvendes under amning.
SIFROL should not be used during breast-feeding.
Sifrol påvirker nerveimpulser i hjernen, som kontrollerer kroppens bevægelser, ved at stimulere dopaminreceptorerne.
Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.
Sifrol tabletter skal synkes hele med vand.
Swallow the tablets whole with water.
Sig det inden behandlingen til din læge eller sygeplejerske (sundhedspersonalet), hvis du:
Before receiving treatment, tell your doctor/nurse (health care professional) if:
Sig det til Deres læge, før De anvender Silapo,, hvis De ved, at De lider af eller har lidt af følgende:
Talk to your doctor before using Silapo if you know you are suffering, or have suffered, from any of the following:
Sig det til Deres læge, før De bruger Retacrit, hvis De ved, at De lider af eller har lidt af følgende:
Talk to your doctor before using Retacrit if you know you are suffering, or have suffered, from any of the following:
Sig det til lægen eller på apoteket, hvis du tager nogen af følgende lægemidler: orale svangerskabsforebyggende midler (se afsnit 2: ”Graviditet og amning”)
Tell your doctor or pharmacist if you are taking any of the following medicines: oral contraceptives (see section 2: ‘Pregnancy and breast-feeding’)
Sig det til lægen før De tager denne medicin, hvis lægen har fortalt Dem, at De ikke tåler visse sukkerarter.
If you have been told by your doctor that you have an intolerance to some sugars, tell your doctor before taking Voriconazole Accord.